Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.

Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2015

Serfaty Lawrence

Abstract excerpt

Second wave direct acting antivirals such as sofosbuvir, simeprevir and daclatasvir can be combined with pegylated interferon alpha and ribavirin (PEG-IFN/RBV) as triple therapy in patients with hepatitis C virus (HCV) infection. In patients with HCV genotype 1 (HCV-1), a PEG-IFN/RBV-based regime...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Heterocyclic Compounds, 3-Ring
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polyethylene Glycols

Share to Pyrrolidines

Share to Simeprevir

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Identifiers

PMID: 25529083
DOI: 10.1111/liv.12722

Genes

IFNL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25529083-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.PMID 25529083Read ↗

How to optimize HCV therapy in genotype 1 patients: predictors of response.Semantic proximity Read ↗

How to optimize current treatment of genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 1 patients with cirrhosis.Semantic proximity Read ↗

Optimal therapy in genotype 1 patients.Semantic proximity Read ↗

[Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].Semantic proximity Read ↗

Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients.Semantic proximity Read ↗

Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.Semantic proximity Read ↗

Treatment of non-genotype 1 hepatitis C virus patients.Semantic proximity Read ↗

Which therapeutic option for hepatitis C virus genotype 1?Semantic proximity Read ↗

Predictors of hepatitis C treatment response: what's new?Semantic proximity Read ↗

Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.Semantic proximity Read ↗

What's new in HCV genotype 2 treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.